Drug Type Antibody oligonucleotide conjugates |
Synonyms GMAB/3p-hpRNA |
Target |
Action inhibitors, stimulants |
Mechanism ENT2 inhibitors(solute carrier family 29 member 2 inhibitors), RIG-I stimulants(Retinoic acid-inducible gene I stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | United States | 10 Apr 2022 |